Sirolimus and Tacrolimus Trough Concentrations and Dose Requirements after Kidney Transplantation in Relation to CYP3A5 and MDR1 Polymorphisms and Steroids-Reference-Cited by-同舟云学术

Sirolimus and Tacrolimus Trough Concentrations and Dose Requirements after Kidney Transplantation in Relation to CYP3A5 and MDR1 Polymorphisms and Steroids

Published:2005-10 Issue:7 Volume:80 Page:977-984
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:Transplantation

Author:

Mourad Michel,Mourad Georges,Wallemacq Pierre,Garrigue Val??rie,Van Bellingen Christophe,Van Kerckhove Val??rie,De Meyer Martine,Malaise Jacques,Eddour Djamila Chaib,Lison Dominique,Squifflet Jean Paul,Haufroid Vincent

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference39 articles.

1. Clinical Pharmacokinetics of Tacrolimus

2. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity

3. A genetic test for immunosuppressant dose selection?

4. Human P-glycoprotein transports cyclosporin A and FK506.

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Steroid–tacrolimus drug–drug interaction and the effect of CYP3A genotypes;British Journal of Clinical Pharmacology;2024-07-12

2. Influence of genetic variants on the pharmacokinetics and pharmacodynamics of sirolimus: a systematic review;Pharmacogenomics;2023-07

3. Precision sirolimus dosing in children: The potential for model-informed dosing and novel drug monitoring;Frontiers in Pharmacology;2023-03-20

4. Influence of CYP3A4 *22 and CYP3A5 *3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients;Journal of Clinical Pharmacy and Therapeutics;2022-11-15

5. Use of Pharmacogenetics to Optimize Immunosuppressant Therapy in Kidney-Transplanted Patients;Biomedicines;2022-07-26